Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Relies On Cognition Research To Spot Misleading Ads – Draft Guidance

This article was originally published in The Gray Sheet

Executive Summary

FDA is harnessing established science on human cognition to assess whether a device or drug maker's advertisement is misleading, according to a May 27 draft 1guidance document from the agency

You may also be interested in...



DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks

Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.

Device Firms Want Their Own Guidelines On Risk Information In Ads

FDA's draft guidance on presentation of risk information in advertisements fails to adequately distinguish between devices and drugs, according to device trade group AdvaMed

Device Firms Want Their Own Guidelines On Risk Information In Ads

FDA's draft guidance on presentation of risk information in advertisements fails to adequately distinguish between devices and drugs, according to device trade group AdvaMed

Related Content

Topics

UsernamePublicRestriction

Register

MT027499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel